Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.5% – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP)’s share price traded down 8.5% on Tuesday . The company traded as low as $14.66 and last traded at $14.55. 28,413 shares were traded during trading, a decline of 71% from the average session volume of 96,459 shares. The stock had previously closed at $15.90.

Rapport Therapeutics Trading Down 4.9 %

The business has a 50-day moving average price of $16.23 and a two-hundred day moving average price of $19.91.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. acquired a new stake in shares of Rapport Therapeutics during the 3rd quarter valued at $1,498,000. Geode Capital Management LLC bought a new position in Rapport Therapeutics in the 3rd quarter worth $4,133,000. State Street Corp bought a new position in Rapport Therapeutics in the 3rd quarter worth $1,189,000. Jennison Associates LLC bought a new position in shares of Rapport Therapeutics during the 4th quarter worth about $1,105,000. Finally, SG Americas Securities LLC bought a new position in shares of Rapport Therapeutics during the 3rd quarter worth about $101,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.